Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

D Kelsen

Showing results (31-40 of 77) with videos related to

Pageof 8
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 25, 1998
UCN-01 suppresses thymidylate synthase gene expression and enhances 5-fluorouracil-induced apoptosis in a sequence-dependent mannerC T Hsueh, D Kelsen, G K Schwartz
Cancer|January 1, 1994
Phase II trial of gemcitabine in patients with advanced gastric cancerK Christman, D Kelsen, L Saltz, et al.
Investigational New Drugs|February 1, 1990
Phase II study of CHIP chemotherapy in advanced adenocarcinomas of the upper gastrointestinal tractA S Goldenberg, D Kelsen, J Dougherty, et al.
Journal of the National Cancer Institute|March 3, 1993
Protein kinase C: a novel target for inhibiting gastric cancer cell invasionG K Schwartz, J Jiang, D Kelsen, et al.
Cancer Treatment Reports|November 1, 1985
Carboplatin: a new platinum analog in the treatment of epidermoid carcinoma of the esophagusC Sternberg, D Kelsen, M Dukeman, et al.
Cancer|August 15, 1990
A phase II trial of recombinant tumor necrosis factor in patients with advanced colorectal carcinomaN Kemeny, B Childs, W Larchian, et al.
Cancer Treatment Reports|March 1, 1984
Phase II trial of mitoguazone in patients with relapsed small cell carcinoma of the lungH Scher, R Chapman, D Kelsen, et al.
Investigational New Drugs|August 1, 1990
Phase II trial of carboplatin and vinblastine in adenocarcinoma of the stomachD Ginn, D Kelsen, M Eisenberger, et al.
Cancer Treatment Reports|March 1, 1987
Phase II trial of etoposide in APUD tumorsD Kelsen, J Fiore, R Heelan, et al.
Journal of the National Cancer Institute|May 19, 1993
Granulocyte colony-stimulating factor: effective in ameliorating fluorouracil-based myelosuppression?K Christman, L Saltz, G Schwartz, et al.
Pageof 8

Showing results (31-40 of 77) with videos related to

Sort By:
Pageof 8
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 25, 1998
UCN-01 suppresses thymidylate synthase gene expression and enhances 5-fluorouracil-induced apoptosis in a sequence-dependent mannerC T Hsueh, D Kelsen, G K Schwartz
Cancer|January 1, 1994
Phase II trial of gemcitabine in patients with advanced gastric cancerK Christman, D Kelsen, L Saltz, et al.
Investigational New Drugs|February 1, 1990
Phase II study of CHIP chemotherapy in advanced adenocarcinomas of the upper gastrointestinal tractA S Goldenberg, D Kelsen, J Dougherty, et al.
Journal of the National Cancer Institute|March 3, 1993
Protein kinase C: a novel target for inhibiting gastric cancer cell invasionG K Schwartz, J Jiang, D Kelsen, et al.
Cancer Treatment Reports|November 1, 1985
Carboplatin: a new platinum analog in the treatment of epidermoid carcinoma of the esophagusC Sternberg, D Kelsen, M Dukeman, et al.
Cancer|August 15, 1990
A phase II trial of recombinant tumor necrosis factor in patients with advanced colorectal carcinomaN Kemeny, B Childs, W Larchian, et al.
Cancer Treatment Reports|March 1, 1984
Phase II trial of mitoguazone in patients with relapsed small cell carcinoma of the lungH Scher, R Chapman, D Kelsen, et al.
Investigational New Drugs|August 1, 1990
Phase II trial of carboplatin and vinblastine in adenocarcinoma of the stomachD Ginn, D Kelsen, M Eisenberger, et al.
Cancer Treatment Reports|March 1, 1987
Phase II trial of etoposide in APUD tumorsD Kelsen, J Fiore, R Heelan, et al.
Journal of the National Cancer Institute|May 19, 1993
Granulocyte colony-stimulating factor: effective in ameliorating fluorouracil-based myelosuppression?K Christman, L Saltz, G Schwartz, et al.
Pageof 8